natgillin/translations-raw huggingface dataset:
Symptomatic, supportive therapy is recommended consisting of administration of gastrointestinal protective agents and infusion of isotonic saline. 
Priporoča se dajanje zaščitnih sredstev za prebavila in infuzija fiziološke raztopine.
Cimalgex 8 mg tablets for dogs Cimalgex 30 mg tablets for dogs Cimalgex 80 mg tablets for dogs cimicoxib 
Cimalgex 8 mg žvečljive tablete za pse Cimalgex 30 mg žvečljive tablete za pse Cimalgex 80 mg žvečljive tablete za pse cimikoksib
NAME OF THE VETERINARY MEDICINAL PRODUCT Cimalgex 8 mg chewable tablets for dogs Cimalgex 30 mg chewable tablets for dogs Cimalgex 80 mg chewable tablets for dogs Cimicoxib 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Cimalgex 8 mg žvečljive tablete za pse Cimalgex 30 mg žvečljive tablete za pse Cimalgex 80 mg žvečljive tablete za pse cimikoksib
NAME OF THE VETERINARY MEDICINAL PRODUCT Cimalgex 8 mg chewable tablets for dogs Cimalgex 30 mg chewable tablets for dogs Cimalgex 80 mg chewable tablets for dogs 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Cimalgex 8 mg žvečljive tablete za pse Cimalgex 30 mg žvečljive tablete za pse Cimalgex 80 mg žvečljive tablete za pse
PHARMACEUTICAL FORM Chewable tablets 
Žvečljive tablete
PACKAGE LEAFLET Cimalgex 8 mg chewable tablets for dogs Cimalgex 30 mg chewable tablets for dogs Cimalgex 80 mg chewable tablets for dogs 
NAVODILO ZA UPORABO Cimalgex 8 mg žvečljive tablete za pse Cimalgex 30 mg žvečljive tablete za pse Cimalgex 80 mg žvečljive tablete za pse
The review looked at data from several studies including: 
V okviru pregleda so bili pregledani podatki iz več študij, med drugim:
• If you have any questions, speak with your doctor or pharmacist. 
• Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
22 May 2015 EMA/325007/2015 
maj 2015 EMA/325007/2015
The review of ibuprofen was initiated on 9 June 2014 at the request of the UK's medicines agency (MHRA), under Article 31 of Directive 2001/83/EC. 
Pregled ibuprofena se je začel dne 9. junija 2014 na zahtevo agencije za zdravila Združenega kraljestva (MHRA) v skladu s členom 31 Direktive 2001/83/ES.
The usual dose for adults and children over 12 years of age is 200 to 400 mg, 3 or 4 times a day as needed. 
Običajni odmerek za odrasle in otroke, starejše od 12 let, je od 200 do 400 mg, 3- ali 4-krat na dan, po potrebi.
Dexibuprofen, the active enantiomer, is sometimes available on its own and is therefore included in this review. 
Deksibuprofen, aktivni enantiomer, je včasih na voljo tudi samostojno, zato je bil prav tako vključen v ta pregled.
The review was conducted by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations. 
Pregled je opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC), ki je odgovoren za presojo varnostnih vprašanj o zdravilih za uporabo v humani medicini, in podal več priporočil.
Risk factors include smoking, high blood pressure, diabetes and high blood cholesterol. 
Dejavniki tveganja so med drugim kajenje, visok krvni tlak, sladkorna bolezen in visoke ravni holesterola v krvi.
1 The CMDh is a medicines regulatory body representing the European Union (EU) Member States, Iceland, Liechtenstein and Norway. 
1 Skupina CMDh je regulativni organ za zdravila, ki zastopa države članice Evropske unije (EU), Islandijo, Lihtenštajn ter Norveško.
It works by blocking an enzyme called cyclooxygenase, which produces prostaglandins, substances that are involved in inflammation and pain. 
Deluje tako, da zavira encim, imenovan ciklooksigenaza, ki proizvaja prostaglandine, snovi, ki sodelujejo pri vnetju in bolečinah.
In addition, doctors should carefully assess a patient's risk factors for heart or circulatory conditions before initiating long-term treatment with ibuprofen, particularly if high doses are required. 
Poleg tega morajo zdravniki pri bolniku skrbno oceniti dejavnike tveganja za bolezni srca ali ožilja, preden predpišejo dolgotrajno zdravljenje z ibuprofenom, zlasti če so potrebni veliki odmerki.
• The effect of duration of ibuprofen treatment on cardiovascular risk is uncertain. 
• Vpliv trajanja zdravljenja z ibuprofenom na srčno-žilno tveganje ni povsem jasen.
As ibuprofen medicines are all authorised nationally, the PRAC recommendations were forwarded to the Co-ordination Group for Mutual Recognition and Decentralised ProceduresHuman (CMDh), which adopted a final position. 
Ker so vsa zdravila, ki vsebujejo ibuprofen, odobrena na nacionalni ravni, so bila priporočila odbora PRAC posredovana Usklajevalni skupini za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMDh), ki je sprejela dokončno stališče.
Ibuprofen and dexibuprofen are currently available in the European Union (EU) in a number of different formulations. 
Ibuprofen in deksibuprofen sta trenutno v Evropski uniji (EU) na voljo v več različnih farmacevtskih oblikah.
Ibuprofen is present in medicines as a mixture of two molecules that are enantiomers (mirror images of each other). 
Ibuprofen je v zdravilih prisoten v obliki zmesi dveh molekul, ki sta enantiomera (zrcalni sliki druga druge).
Reviews carried out in 2005, 2006, and 2012 confirmed that NSAIDs as a class are associated with a small increase in the risk of arterial thromboembolic events (blood clots in the arteries) especially in patients with underlying heart or circulatory conditions or with certain cardiovascular risk factors, and particularly if used at high doses. 
Pregledi, ki so jih opravili v letih 2005, 2006 in 2012, so potrdili, da je skupina nesteroidnih protivnetnih zdravil povezana z rahlo povečanim tveganjem za arterijske trombembolične dogodke (krvne strdke v arterijah), zlasti pri bolnikih z obstoječimi boleznimi srca in ožilja ali z določenimi srčno-žilnimi dejavniki tveganja, zlasti kadar se zdravila uporabljajo v velikih odmerkih.
Laboratory studies have shown that ibuprofen reduces the blood-thinning effects of aspirin. 
Laboratorijske študije so pokazale, da ibuprofen zmanjša učinke aspirina na redčenje krvi.
A class warning of this risk is already in place and the product information for all NSAIDs, including ibuprofen, recommends that these medicines be used at the lowest effective dose and for the shortest period of time necessary to control symptoms. 
Za to skupino je že bilo izdano opozorilo o omenjenem tveganju, informacije o zdravilu za vsa nesteroidna protivnetna zdravila, tudi za ibuprofen, pa vsebujejo priporočilo, naj se ta zdravila uporabljajo pri najmanjšem učinkovitem odmerku in najkrajši možni čas, ki je potreben za obvladanje simptomov.
They are available on prescription and over the counter. 
Izdajajo se na recept in brez recepta.
The review covered formulations for systemic use (intended to act on the whole body, such as use by mouth or by injection); it did not cover formulations such as gels or sprays applied to the skin of the affected area. 
V pregled so bile vključene farmacevtske oblike za sistemsko uporabo (ki naj bi delovale na celotno telo in se uporabljajo npr. skozi usta ali z injiciranjem), ne pa tudi farmacevtske oblike, kot so geli ali pršila, ki se nanesejo na kožo prizadetega predela.
Occasional use of ibuprofen should not affect the benefits of low-dose aspirin. 
Občasna uporaba ibuprofena ne bi smela vplivati na koristi nizkoodmernega aspirina.
• Your doctor will carefully assess you before starting treatment with high-dose ibuprofen to check if you have risk factors such as high blood pressure, high blood cholesterol, diabetes, or if you smoke. 
• Preden boste začeli zdravljenje z velikim odmerkom ibuprofena, vas bo zdravnik skrbno ocenil, da bi preveril, ali so pri vas prisotni dejavniki tveganja, kot so visok krvni tlak, visoke ravni holesterola v krvi, sladkorna bolezen ali kajenje.
• Experimental data suggest long-term use of ibuprofen/dexibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid (typically 75 mg per day). 
• Eksperimentalni podatki kažejo, da bi dolgotrajna uporaba ibuprofena/deksibuprofena lahko zmanjšala kardioprotektivne učinke nizkoodmerne acetilsalicilne kisline (običajno v odmerku 75 mg na dan).
A dose of 2,400 mg per day of ibuprofen is equivalent to 1,200 mg per day of dexibuprofen. 
Odmerek ibuprofena 2400 mg na dan je enakovreden odmerku deksibuprofena 1200 mg na dan.
On 20 May 2015 the CMDh adopted its position by consensus, therefore the advice recommended by the PRAC will be implemented by the Member States where the medicines are authorised, according to an agreed timetable. 
Skupina CMDh je dne 20. maja 2015 soglasno sprejela dokončno stališče, zato bodo države članice, v katerih so zdravila odobrena, morale izvajati priporočila odbora PRAC v skladu z dogovorjenim časovnim razporedom.
The CMDh1 has endorsed by consensus updated advice on the use of high-dose ibuprofen. 
Skupina CMDh1 je soglasno podprla posodobljena priporočila za uporabo velikih odmerkov ibuprofena.
• Patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking) should only be treated with high-dose ibuprofen after careful consideration. 
• Bolnike z dejavniki tveganja za srčno-žilne dogodke (npr. hipertenzija, hiperlipidemija, sladkorna bolezen in kajenje) se lahko zdravi z velikimi odmerki ibuprofena šele po temeljitem razmisleku.
However, it remains uncertain whether longterm use of ibuprofen in clinical practice reduces the benefits of low-dose aspirin in preventing heart attacks and strokes. 
Vendar še vedno ni jasno, ali dolgotrajna uporaba ibuprofena v klinični praksi zmanjša koristi nizkoodmernega aspirina pri preprečevanju srčnih in možganskih kapi.
Ibuprofen and dexibuprofen medicines have been authorised in the EU through national approval procedures and have been available for many years under a wide range of trade names. 
Zdravila, ki vsebujejo ibuprofen in deksibuprofen, so bila v EU odobrena po nacionalnih postopkih in so že več let na voljo pod različnimi tržnimi imeni.
For diclofenac, the risk was estimated at about 3 extra cases of heart attack in every 1,000 patients taking diclofenac for a year. 
Tveganje pri uporabi diklofenaka po ocenah zajema približno 3 dodatne primere srčne kapi na vsakih 1000 bolnikov, ki eno leto jemljejo diklofenak.
This is because ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are used concomitantly. 
Ibuprofen lahko namreč kompetitivno zavira učinek nizkoodmerne acetilsalicilne kisline na agregacijo trombocitov, kadar se zdravili uporabljata sočasno.
More about the safety of NSAIDs 
Več o varnosti nesteroidnih protivnetnih zdravil
For diclofenac, the risk was estimated at around three additional major vascular events per 1,000 participants per year. 
Tveganje pri uporabi diklofenaka po ocenah zajema približno tri dodatne pomembnejše vaskularne dogodke na 1000 bolnikov na leto.
• High doses of ibuprofen should be avoided in patients with cardiovascular conditions (e.g. uncontrolled hypertension, congestive heart failure (NYHA class II-III), established ischaemic heart disease, peripheral arterial disease and cerebrovascular disease). 
• Uporabi velikih odmerkov ibuprofena se je treba izogibati pri bolnikih s srčno-žilnimi boleznimi (kot so npr. nenadzorovana hipertenzija, kongestivno srčno popuščanje (razreda II-III po NYHA), ugotovljena ishemična bolezen srca, periferna arterijska bolezen in možgansko-žilna bolezen).
• Use of high-dose ibuprofen is no longer recommended if you have heart or circulatory conditions, such as heart failure, heart disease and circulatory problems or if you have previously had a heart attack or stroke. 
• Uporaba velikih odmerkov ibuprofena ni več priporočljiva, če imate bolezni srca ali ožilja, kot so srčno popuščanje, bolezen srca in težave z ožiljem, ali če ste že kdaj doživeli srčno ali možgansko kap.
The updated advice on the cardiovascular risk of high-dose ibuprofen will be included in the product information of ibuprofen medicines, along with information on the interaction between ibuprofen and aspirin. 
Posodobljena priporočila v zvezi s srčno-žilnim tveganjem, povezanim z uporabo velikih odmerkov ibuprofena, bodo vključena v informacije o zdravilih, ki vsebujejo ibuprofen, skupaj z informacijami o medsebojnem delovanju ibuprofena in aspirina.
To minimise the cardiovascular risk, high doses of ibuprofen (2,400 mg per day or higher) should be avoided in patients with serious underlying heart or circulatory conditions, such as heart failure, heart disease and circulatory problems or in those who have previously had a heart attack or stroke. 
Da bi zmanjšali srčno-žilno tveganje, se je treba uporabi velikih odmerkov ibuprofena (2400 mg na dan ali več) izogibati pri bolnikih z resnimi osnovnimi boleznimi srca ali ožilja, kot so srčno popuščanje, bolezen srca in težave z ožiljem, ter pri tistih, ki so že kdaj doživeli srčno ali možgansko kap.
Updated advice on use of high-dose ibuprofen 
Posodobljena priporočila za uporabo velikih odmerkov ibuprofena
Ibuprofen is a painkiller and anti-inflammatory medicine that belongs to the class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). 
Ibuprofen je zdravilo proti bolečinam in protivnetno zdravilo, ki spada v razred nesteroidnih protivnetnih zdravil (NSAID).
Review confirms small cardiovascular risk with daily doses at or above 2,400 mg 
Pregled je potrdil majhno srčno-žilno tveganje pri uporabi dnevnih odmerkov 2400 mg ali več
• Prolonged use of ibuprofen may reduce the effect of low-dose aspirin when the latter is taken to reduce the risk of heart attacks and strokes. 
• Dolgotrajnejša uporaba ibuprofena lahko zmanjša učinke nizkoodmernega aspirina, ki se jemlje za zmanjšanje tveganja za srčne in možganske kapi.
This latest review considered accumulated evidence which clarifies the cardiovascular risk related to ibuprofen taken at high doses and the interaction between ibuprofen at any dose and aspirin. 
V zadnjem pregledu so proučili nakopičene dokaze, ki pojasnjujejo, kakšno je srčno-žilno tveganje, povezano z velikimi odmerki ibuprofena, in medsebojno delovanje ibuprofena v katerem koli odmerku in aspirina.
• Although no specific data about the cardiovascular risk with dexibuprofen are available, a similar cardiovascular risk to that with high-dose of ibuprofen is expected when dexibuprofen is used at equipotent doses (at or above 1,200 mg per day). 
• Kljub temu da niso na voljo nobeni specifični podatki o srčno-žilnem tveganju, povezanem z deksibuprofenom, je mogoče pričakovati podobno srčno-žilno tveganje pri uporabi velikih odmerkov ibuprofena in odmerkov deksibuprofena enakih jakosti (1200 mg na dan ali več).
The review also looked at data on the interaction between ibuprofen and low-dose aspirin when the latter is taken to reduce the risk of heart attacks and strokes. 
V okviru pregleda so proučili tudi podatke o medsebojnem delovanju ibuprofena in nizkoodmernega aspirina, ki se jemlje za zmanjšanje tveganja za srčne in možganske kapi.
• An EU-wide review of ibuprofen has confirmed that there is a small risk of heart attacks and strokes in patients taking high doses of the medicine (at or above 2,400 mg per day). 
• Pregled ibuprofena po vsej EU je potrdil, da obstaja majhno tveganje za srčne in možganske kapi pri bolnikih, ki jemljejo velike odmerke zdravila (2400 mg na dan ali več).
As the CMDh has now agreed the PRAC advice by consensus, changes to the product information for ibuprofen- and dexibuprofen-containing medicines will be implemented by the Member States where the medicines are authorised, according to an agreed timetable. 
Ker se je skupina CMDh soglasno strinjala s priporočili odbora PRAC, bodo države članice, v katerih so zdravila odobrena, spremenile informacije o zdravilu za zdravila, ki vsebujejo ibuprofen in deksibuprofen, v skladu z dogovorjenim časovnim razporedom.
This follows a review carried out by EMA's Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed a small increased risk of cardiovascular problems, such as heart attacks and strokes, in patients taking high doses of ibuprofen (at or above 2,400 mg per day). 
Podlaga je bila pregled, ki ga je opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC) pri Evropski agenciji za zdravila in ki je potrdil rahlo povečano tveganje za srčno-žilne zaplete, kot so srčne in možganske kapi, pri bolnikih, ki jemljejo velike odmerke ibuprofena (2400 mg na dan ali več).
No risk has been seen with ibuprofen at doses up to 1,200 mg per day, which is the highest dose usually taken by the majority of patients. 
Pri uporabi odmerkov ibuprofena do 1200 mg na dan, kar je največji odmerek, ki ga običajno jemlje večina bolnikov, tveganja niso opazili.
No clinically relevant effect is considered to be likely for occasional ibuprofen use. 
Pri občasni uporabi ibuprofena ni pričakovati klinično pomembnega vpliva.
• Data from meta-analyses and epidemiological studies indicate that there is an increased risk of cardiovascular events (such as myocardial infarction or stroke) associated with the use of highdose ibuprofen (at or above 2,400 mg per day).1-4 
• Podatki iz metaanaliz in epidemioloških študij kažejo, da je z uporabo velikih odmerkov ibuprofena (2400 mg na dan ali več) povezano povečano tveganje za srčno-žilne dogodke (kot sta srčni infarkt in možganska kap).1-4
It followed concerns that high doses of ibuprofen could have a similar cardiovascular risk to that of COX-2 inhibitors and diclofenac. 
Pregled je bil sprožen zaradi zaskrbljenosti, da bi veliki odmerki ibuprofena lahko bili povezani s podobnim srčno-žilnim tveganjem kot zaviralci COX-2 in diklofenak.
• The risk with high-dose ibuprofen is similar to the risk seen with some other non-steroidal antiinflammatory drugs (NSAIDs), including COX-2 inhibitors and diclofenac. 
• Tveganje pri uporabi velikih odmerkov ibuprofena je podobno tveganju, ki ga opažajo pri uporabi nekaterih drugih nesteroidnih protivnetnih zdravil, med drugim zaviralcev COX-2 in diklofenaka.
You should therefore always seek the advice of your doctor or pharmacist before using ibuprofen with aspirin. 
Preden uporabite ibuprofen skupaj z aspirinom, se zato vedno posvetujte z zdravnikom ali s farmacevtom.
No increase in cardiovascular risk is seen with ibuprofen at doses of up to 1,200 mg per day, which is the highest dose generally used for over-the-counter (OTC) preparations taken by mouth in the European Union (EU). 
Povečanega srčno-žilnega tveganja pa niso opazili pri uporabi ibuprofena v odmerkih do 1200 mg na dan, kar je največji odmerek, ki se običajno uporablja v EU pri farmacevtskih oblikah, ki se jemljejo peroralno in se izdajajo brez recepta.
The safety of NSAIDs, including ibuprofen, has been reviewed regularly by authorities in the EU over the past few years. 
Zadnjih nekaj let organi v EU redno ocenjujejo varnost nesteroidnih protivnetnih zdravil, med drugim tudi ibuprofena.
The review clarifies that the risk with highdose ibuprofen is similar to the risk seen with some other non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors and diclofenac. 
Pregled je pokazal, da je tveganje pri uporabi velikih odmerkov ibuprofena podobno tveganju, ki ga opažajo pri uporabi nekaterih drugih nesteroidnih protivnetnih zdravil, med drugim zaviralcev COX-2 in diklofenaka.
This summary was last updated in 05-2009. 
Ta povzetek je bil nazadnje posodobljen 05-2009.
It is available as capsules (yellow: 1.5 mg, orange: 3 mg, brownish red: 4.5 mg, and brownish red and orange: 6 mg) and as white orodispersible tablets (1.5 mg, 3 mg, 4.5 mg, and 6 mg). 
Na voljo je v obliki kapsul (rumenih: 1,5 mg, oranžnih: 3 mg, rjavkasto rdečih: 4,5 mg in rjavkasto rdečih in oranžnih: 6 mg) ter v obliki belih orodisperzibilnih tablet (1,5 mg, 3 mg, 4,5 mg in 6 mg).
Other information about Nimvastid: 
Druge informacije o zdravilu Nimvastid:
The European Commission granted a marketing authorisation valid throughout the European Union for Nimvastid to KRKA,d.d., Novo mesto on 11 May 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Nimvastid, veljavno po vsej Evropski uniji, odobrila družbi KRKA,d.d., Novo mesto dne 11. maja 2009.
This means that Nimvastid is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon. 
To pomeni, da je zdravilo Nimvastid podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Exelon.
The Committee recommended that Nimvastid be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Nimvastid odobri dovoljenje za promet.
What are the benefit and risk of Nimvastid? 
Kakšne so koristi in tveganja, povezana z zdravilom Nimvastid?
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NIMVASTID EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) NIMVASTID Povzetek EPAR za javnost
The starting dose for Nimvastid is 1.5 mg twice a day. 
Začetni odmerek zdravila Nimvastid je 1,5 mg dvakrat na dan.
Nimvastid is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 
Zdravilo Nimvastid se uporablja za zdravljenje bolnikov z blago do zmerno hudo alzheimerjevo demenco, napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
Why has Nimvastid been approved? 
Zakaj je bilo zdravilo Nimvastid odobreno?
Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects. 
Zdravljenje je treba nadaljevati, dokler je zdravilo učinkovito, vendar se lahko odmerek zniža in zdravljenje prekine, če se pri bolniku pojavijo neželeni učinki.
Treatment with Nimvastid should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease. 
Zdravljenje z zdravilom Nimvastid mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem alzheimerjeve bolezni ali demence pri bolnikih s parkinsonovo boleznijo.
Nimvastid is a ‘generic medicine'. 
Zdravilo Nimvastid je „generično zdravilo“.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Nimvastid has been shown to have comparable quality and to be bioequivalent to Exelon. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Nimvastid primerljivo raven kakovosti kot zdravilo Exelon ter da mu je biološko enakovredno.
Nimvastid orodispersible tablets should be placed on the tongue, where they disintegrate quickly in the saliva before being swallowed. 
Orodisprezibilne tablete Nimvastid se položijo na jezik, kjer se v slini hitro razgradijo, preden jih bolnik pogoltne.
Because Nimvastid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine. 
Glede na to, da je Nimvastid generično zdravilo in je bioekvivalentno referenčnemu zdravilu, ima enake koristi in tveganja kot referenčno zdravilo.
Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. 
Rivastigmin deluje tako, da zavira encime, ki razgrajujejo acetilholin: acetilholinesterazo in butirilholinesterazo.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Nimvastid by the patient. 
Zdravljenje se začne samo ob prisotnosti negovalca, ki redno nadzoruje uporabo zdravila Nimvastid pri bolniku.
Because Nimvastid is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body). 
Ker je zdravilo Nimvastid generično zdravilo, so bile študije omejene na preskuse, s katerimi se dokazuje, da je biološko enakovredno referenčnemu zdravilu (tj. da zdravili dosegata enake ravni zdravilne učinkovine v telesu).